<SEC-DOCUMENT>0001140361-22-024840.txt : 20220901
<SEC-HEADER>0001140361-22-024840.hdr.sgml : 20220901
<ACCEPTANCE-DATETIME>20220701172225
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-22-024840
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEOGEN CORP
		CENTRAL INDEX KEY:			0000711377
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				382367843
		STATE OF INCORPORATION:			MI
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		620 LESHER PLACE
		CITY:			LANSING
		STATE:			MI
		ZIP:			48912
		BUSINESS PHONE:		5173729200

	MAIL ADDRESS:	
		STREET 1:		620 LESHER PLACE
		CITY:			LANSING
		STATE:			MI
		ZIP:			48912
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right;">
      <div><img src="ny20004078x13_img01.jpg" height="21" width="289"></div>
      <div style="text-align: left;"><br>
      </div>
    </div>
    <div style="font-size: 8pt;">
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">767 Fifth Avenue<br>
        New York, NY 10153-0119<br>
        +1 212 310 8000 tel<br>
        +1 212 310 8007 fax</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">July 1, 2022</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"><u>Via EDGAR</u><br>
      </font><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Abby Adams</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Christine Westbrook</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Division of Corporation Finance</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Office of Life Sciences</div>
    <div style="font-family: 'Times New Roman',Times,serif;">U.S. Securities and Exchange Commission</div>
    <div style="font-family: 'Times New Roman',Times,serif;">100 F Street, NE</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Washington, D.C.&#160; 20549</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3cf4464766a243029abbebf7b7d17924" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Re:</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Neogen Corporation<br>
              Amendment No. 2 to Registration Statement on Form S-4<br>
              Filed on June 8, 2022<br>
              File No. 333-263667</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Dear Ms. Adams and Ms. Westbrook:</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">On behalf of our client, Neogen Corporation (the &#8220;<u>Company</u>&#8221;), set forth below is the response of the Company to the comments of the Staff of the Division of Corporation
      Finance (the &#8220;<u>Staff</u>&#8221;) that were set forth in your letter dated June 24, 2022, regarding Amendment No. 2 to Registration Statement on Form S-4 (the &#8220;<u>Registration Statement</u>&#8221;) filed by the Company with the Securities and Exchange
      Commission on June 8, 2022.&#160; In connection with this letter responding to the Staff&#8217;s comments, the Company is today filing Amendment No. 3 to the Registration Statement (&#8220;<u>Amendment No. 3</u>&#8221;).&#160; To the extent that comments to the Registration
      Statement are applicable to disclosure in the revised Preliminary Proxy Statement on Schedule 14A filed by the Company on June 9, 2022, or to the Registration Statement on Form S-4 (Reg. No. 333-263669) filed by Garden SpinCo Corporation (&#8220;<u>Garden
      </u>SpinCo&#8221;) on June 8, 2022, Neogen or Garden SpinCo, as applicable, has revised such documents accordingly and is filing an amendment thereto via EDGAR substantially concurrently to the submission of Amendment No. 3.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">For your convenience, the Staff&#8217;s comments are set forth in bold, followed by the response on behalf of the Company.&#160; All page references in the response set forth below refer
      to pages of Amendment No. 3.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Amendment No. 2 to Registration Statement on Form S-4</u></div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Non-GAAP Financial Measures, page 69</u></div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcaa96be4a23d4b0d8ff9e2fe6832fcc9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">1.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">We note your non-GAAP presentation, and have the following comments:</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32e70059dc654a8da4fd083dd0f6d786" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt; vertical-align: top;">
              <div style="margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Please disclose the purpose management uses the presented non-GAAP financial measures. Refer to Item 10(e)(1)(i)(D) of Regulation S-K or direct us to existing
                disclosure.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Response</u></font><font style="font-size: 10pt;">:&#160; The Company respectfully acknowledges the Staff&#8217;s comment and has
        revised the disclosure on pages 69 and 70 of Amendment No. 3.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif;">In addition, although neither Company management nor the management of the Food Safety Business has historically used the presented non-GAAP measures for
      managing their respective businesses, the Company respectfully notes that Item 10(e)(1)(i)(D) of Regulation S-K, as clarified by Question 102.04 of the U.S. Securities and Exchange Commission&#8217;s Compliance &amp; Disclosure Interpretations for Non-GAAP
      Financial Measures, does not prohibit disclosure of a non-GAAP financial measure that is not used by management in managing its business. The Company believes that presentation of these metrics in this context may be useful to investors for the
      reasons described in the prospectus. Furthermore, the Company believes that these non-GAAP financial measures will be used following the Closing as the basis for calculations to determine the combined company&#8217;s compliance with certain covenants in
      the documents governing the debt financing expected to be consummated in connection with the Transactions.</div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18a429b0f0054650a503acdba3429470" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt; vertical-align: top;">
              <div style="margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Please revise to provide the reason(s) that are more substantively specific to you why management believes that each non-GAAP measure disclosed provides useful
                information to investors in light of the limitations listed on page 70.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Response</u></font><font style="font-size: 10pt;">: The Company respectfully acknowledges the Staff&#8217;s comment and has revised
        the disclosure on pages 69 and 70 of Amendment No. 3.</font></div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zebd892899bf8456aac6eea4188a38e2b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt; vertical-align: top;">
              <div style="margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Please include a presentation, with equal or greater prominence, of the most directly comparable GAAP financial measure to Adjusted EBITDA margin.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Response</u></font><font style="font-size: 10pt;">: The Company acknowledges the Staff&#8217;s comment and has revised the
        disclosure on pages 38, 39 and 41 through 44 of Amendment No. 3.</font></div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdba9ab8f139d411aa64fa145e9f755b9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt; vertical-align: top;">
              <div style="margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">You state that Neogen defines Pro Forma EBITDA as &#8220;net income&#8221; before interest, income taxes, and depreciation and amortization. Please revise to properly identify
                net income in this instance as &#8220;pro forma net income&#8221; here and in the table and footnote 2 on page 44.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Response</u></font><font style="font-size: 10pt;">: The Company respectfully acknowledges the Staff&#8217;s comment and has revised
        the disclosure on pages 44 and 70 of Amendment No. 3.</font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Information About the Food Safety Business</u></div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Intellectual Property, page 94</u></div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z635ae453480b4ab9a9c286fc48260e76" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">2.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">We note your response to prior comment 3 and the footnote to the table beginning on page 94 indicating disclosure in the last column denotes the number of patents or
                patent applications that are pending or issued in the applicable jurisdiction. Please revise the table so that the disclosure clearly distinguishes patent applications from issued patents.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div style="margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Response</u></font><font style="font-size: 10pt;">: The Company respectfully acknowledges the Staff&#8217;s comment and has revised
        the disclosure on pages 95 through 98 of Amendment No. 3.</font></div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Unaudited Pro Forma Condensed Combined Financial Information of Neogen and the Food Safety Business, page 102</u></div>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08d53b7956b64d5a989cbfd1adcadeca" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">3.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Your response did not provide the information requested by our prior comment 7, and we reissue the comment. In order to help us further evaluate your pro forma
                financial information, please analyze for us whether the transition arrangements described beginning on page 194 and the other four agreements described beginning on page 193 are required to be given pro forma effect pursuant to Rule 11-01
                of Regulation S-X. In your response, please clarify how that pro forma effect would be computed.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div style="margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Response</u></font><font style="font-size: 10pt;">:&#160; <font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">The Company respectfully acknowledges the Staff&#8217;s comment and appreciates the opportunity to discuss with the Staff the response previously provided by the Company in its letter dated June 8, 2022 with respect to the Staff&#8217;s prior comment
          7. Consistent with such discussion, the Company respectfully refers the Staff to the Company&#8217;s response to prior comment 7 included in its response letter filed on June 8, 2022, and has revised the disclosure on pages 118 and 119 of Amendment No.
          3 to include an explanation that the unaudited pro forma condensed combined financial information does not include a transaction accounting adjustment for the Clean-Trace Distribution Agreement.</font></font></div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif;">*</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 28.8pt; font-family: 'Times New Roman',Times,serif;">If you have any questions concerning the Registration Statement or require any additional information, please do not hesitate to contact me at (212) 310-8268 or
      eoghan.keenan@weil.com or my colleague Michael J. Aiello at (212) 310-8552 or michael.aiello@weil.com.</div>
    <div>&#160;</div>
    <div>
      <table id="ze75c426f7c2549ce8fa9dcf94497495e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 65%;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%;"><font style="font-family: 'Times New Roman',Times,serif;">Sincerely yours,</font></td>
          </tr>
          <tr>
            <td style="width: 65%;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 65%;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%;">/s/ Eoghan P. Keenan</td>
          </tr>
          <tr>
            <td style="width: 65%;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%;">Eoghan P. Keenan</td>
          </tr>

      </table>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"> </font><br>
    </div>
    <div>
      <table id="zaeef7b492d514b3fa2221309798ff771" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%;">cc:</td>
            <td style="width: 95%;">Amy M. Rocklin, Neogen Corporation</td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 95%;">Michael J. Aiello, Weil, Gotshal &amp; Manges LLP</td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 95%;">Michelle A. Sargent, Weil, Gotshal &amp; Manges LLP</td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 95%;">Mojdeh Poul, Garden SpinCo Corporation</td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 95%;">Kevin Rhodes, Garden SpinCo Corporation</td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 95%;">Steven A. Rosenblum, Wachtell, Lipton, Rosen &amp; Katz</td>
          </tr>
          <tr>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 95%;">Jenna E. Levine, Wachtell, Lipton, Rosen &amp; Katz</td>
          </tr>

      </table>
      &#160;</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ny20004078x13_img01.jpg
<TEXT>
begin 644 ny20004078x13_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 2(# 2(  A$! Q$!_\0
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M[HF=08GC' X\L)D9R-^01D8XN'3M1\.^!O"WC*'3X/W>MS2QSOM/F;1"8E8
MABN^&?CC&#TW D ZCPU\4_B!<^)ECU'7X'TS3I5FU1Q':[%MEE5)"KJOSYW
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) '44444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
